Ashley Easter shared a post on LinkedIn:
โSeven years ago, I had the opportunity to join AstraZeneca to work on the development of oncology diagnostics. I now work in the Global Oncology Diagnostics team, solving complex in-market diagnostic problems and improving patient access to testing and treatments.
Today, I wanted to reflect on my journey โ letโs take a look back!
๐๐ฆ๐ฉ๐ซ๐จ๐ฏ๐ข๐ง๐ ๐๐๐๐๐ฌ๐ฌ ๐ญ๐จ ๐๐๐ ๐ญ๐๐ฌ๐ญ๐ข๐ง๐ ๐ก๐๐ฌ ๐๐๐๐ง ๐ญ๐ก๐ ๐ก๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ ๐จ๐ ๐ฆ๐ฒ ๐๐๐ซ๐๐๐ซ ๐ฌ๐จ ๐๐๐ซ: Our teamโs work on improving access to HRD testing has been highly impactful and rewarding. Weโre now looking forward to applying the same philosophy of democratisation to tackle even greater diagnostic challenges in the near future.
๐๐ก๐๐ง๐ ๐ข๐ง๐ ๐๐ข๐๐ ๐ง๐จ๐ฌ๐ญ๐ข๐ ๐๐ฉ๐ฉ๐ซ๐จ๐๐๐ก๐๐ฌ: The broadening of diagnostic approaches, including widespread NGS panel testing, real-world implementation of genetic signatures and the application of novel AI techniques is bringing great benefits for patients and physicians.
Moving forwards, we need to find efficiencies, consolidate testing approaches and improve the provision of diagnostic information provided to MDTs.
๐๐ฆ๐ฉ๐๐๐ญ๐๐ฎ๐ฅ ๐ฅ๐๐๐ซ๐ง๐ข๐ง๐ ๐ฌ: Weโre always evolving and learning from our in-market colleagues, external experts and diagnostic partner companies to optimise how we work.
For instance, weโre aiming to understand the workflow challenges of new sample types or the need for yet another biomarker test from the same tissue sample.
๐๐ก๐๐ญ ๐ญ๐ก๐ ๐๐ฎ๐ญ๐ฎ๐ซ๐ ๐ก๐จ๐ฅ๐๐ฌ: Weโre set to bring novel approaches to market, and Iโm excited to see these being adopted in real-world practice to benefit patients.
Every new biomarker and test comes with challenges, but weโve got the team, the experience and the partnerships in place to deliver on cutting-edge science.
Thank you to my wonderful team, colleagues and leaders who have all made the last seven years such a fulfilling and exciting time โ I look forward to our work ahead!!โ
Source: Ashley Easter/LinkedIn
Ashley Easter is the Head of Strategy and Partnerships and Global Oncology Diagnostics at AstraZeneca. Previously he was a Board Member at Precision Cancer Consortium and an Innovation Consultant and Project Manager at Innovia Technology.
